Novartis books multimillion-dollar sales of Genmab-developed drug in Q1

Novartis’s sales of Kesimpta, a sclerosis drug developed by Genmab, are up by 290 percent in the first quarter of 2022 compared to Q1 2021.
by christian bundgaard, translated by daniel pedersen

Swiss Novartis has lit a fire under its sales of Genmab-developed multiple sclerosis drug Kesimpta, evidenced by Novartis’s financial report for the first quarter of the year.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading